Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Episcleral Celecoxib
- Development stage
- Unknown
- Lead developer
- Targeted Therapy Technologies
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Episcleral Celecoxib is an investigational, sustained-release formulation of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, developed by Targeted Therapy Technologies, LLC. It is designed as a sequestered transscleral, controlled-release episcleral exoplant (reservoir) that delivers the drug through transscleral diffusion to the retina and choroid. This delivery method is intended to provide long-term therapeutic drug levels to the posterior pole of the eye while being less invasive than repeated intraocular injections. The formulation is primarily being evaluated for the treatment of macular edema and other inflammatory or neovascular disorders of the retina, choroid, and vitreous. Preclinical studies have shown that this delivery method significantly inhibits retinal and choroidal neovascularization by reducing vascular endothelial growth factor (VEGF) expression and vascular leakage.
- Other names
- Sequestered Transscleral Controlled-Release CelecoxibEpiscleral Celecoxib Reservoir
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Episcleral Celecoxib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Episcleral Celecoxib.